aTyr Pharma submits Phase 3 efzofitimod trial protocol to FDA for pulmonary sarcoidosis study

• aTyr Pharma completed enrollment in its Phase 2 EFZO-CONNECT study of efzofitimod in SSc-ILD; topline results are expected in Q1 2027.
• The study is designed to assess whether efzofitimod can improve patient condition and symptoms versus placebo; no new results were reported.
• A Phase 3 pulmonary sarcoidosis trial is planned; FDA feedback on the submitted protocol is expected by end-August 2026.
• The Phase 3 trial aims to test whether efzofitimod can slow or reverse lung function decline while improving patient-reported outcomes.
• Management prioritized efzofitimod in ILD to conserve cash ahead of late-stage development; cash and investments totaled $58.9 million at June 30, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001339970-26-000051), on August 07, 2026, and is solely responsible for the information contained therein.